Toutes les études
RecrutementPHASE3INTERVENTIONNEL

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

This research study is looking at a new treatment called NXT007 for people with haemophilia A, a condition where blood doesn't clot properly. It's being compared to an existing treatment called emicizumab. The study is open to people aged 12 and older who have severe, moderate, or even mild haemophilia A, particularly if they have developed 'inhibitors' which make standard treatments less effective. Researchers want to understand if NXT007 is safe, how effective it is at preventing bleeding, and how it acts in the body, to potentially offer another helpful option for managing this condition.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Hoffmann-La Roche
Objectif d'inscription
360
Démarrer
27 Apr 2026
Achèvement estimé
29 Jan 2032

De quoi parle cette étude ?

This study is investigating a new medication called NXT007 for people living with haemophilia A. Haemophilia A is a condition that means your blood doesn't clot as it should, leading to longer bleeding and sometimes internal bleeding. People with haemophilia often take regular medication to help prevent these bleeds, a treatment approach known as 'prophylaxis'. This study aims to see if NXT007 can be an effective and safe option for preventing bleeds, similar to or better than an existing treatment called emicizumab.

The main goal is to find out how well NXT007 works compared to emicizumab. The researchers will be looking at several things, including how effective the treatments are at stopping bleeds, if there are any side effects (safety), and how the medications behave inside the body. This information is really important because it helps doctors understand which treatments are best for different people with haemophilia A.

The study includes people aged 12 and above. It's open to those with severe or moderate haemophilia A, and also to people with any severity (mild, moderate, or severe) who have developed 'inhibitors'. Inhibitors are antibodies that the body sometimes makes against treatment, making it less effective. Finding new treatments for people with inhibitors is particularly important as their options can be more limited.

Points clés

  • Compares a new drug (NXT007) with an existing one (emicizumab) for haemophilia A.
  • Aimed at people 12 years and older, including those with 'inhibitors'.
  • Focuses on preventing bleeds, safety, and how the drugs work.
  • Involves regular clinic visits and close medical monitoring.
  • La participation est volontaire, et vous pouvez vous retirer à tout moment.

Qui peut être éligible ?

To join this study, you generally need to be 12 years or older and have a confirmed diagnosis of haemophilia A. This includes people with severe or moderate forms of the condition, whether they have developed 'inhibitors' (which make some treatments less effective) or not. If you have mild haemophilia A, you can still participate, but only if you have developed chronic inhibitors that significantly reduce your natural clotting ability.

The doctors will also need to review your past medical records, including information about any previous treatments for haemophilia and bleeding episodes, especially over the last six months. If you currently take medication only when you have a bleed, you would need to be willing to switch to a regular preventative treatment with either NXT007 or emicizumab as part of the study.

There are also some reasons why you might not be able to join. For example, if you are allergic to any part of the study treatments or tests, or if you are taking certain other medications that could interfere with the study. Also, if you have certain heart conditions or are planning major surgery during the study period, you wouldn't be able to take part. The study team will discuss all these details with you carefully.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you 12 years old or older?
  2. Have you been diagnosed with severe or moderate haemophilia A?
  3. If you have mild haemophilia A, do you also have 'inhibitors' that significantly reduce your clotting ability?
  4. Are you willing to switch to a regular preventative treatment if you're currently taking medication only when you bleed?
  5. Do you have any heart conditions or major surgeries planned during the study period?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part in this study, you will be given either the new medication NXT007 or the existing treatment emicizumab on a regular schedule, as a preventative measure against bleeding. This will be decided randomly, like flipping a coin. You will have regular visits to the clinic where doctors and nurses will monitor your health, perform various tests, and check for any side effects. You'll also be asked to keep a record of any bleeding episodes you experience.

The study involves several clinic visits over a period of time, where you'll have blood tests, physical examinations, and answer questions about how you're feeling. The exact number and frequency of visits will be explained by the study team. You'll be closely supported by the medical team throughout your participation. The total duration of the study for each person will vary, but it typically involves an initial treatment period followed by ongoing monitoring.

Risques et avantages potentiels

Participating in this study could offer some potential benefits, such as receiving a new investigational treatment (NXT007) or an established treatment (emicizumab) for your haemophilia A, and close monitoring of your health by a specialist team. However, there are also potential risks. New medications can have side effects that are not yet fully known, or you might experience side effects from either treatment. There's also the chance that the treatment might not work as well for you as expected. All study procedures, like blood tests, carry small risks. You will be fully informed about all known risks before you decide to join, and you are always free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (63)

  • Center for Inherited Blood Disorders
    Code postal vérifié
    Orange, United States· Recrutement
  • University of Colorado Hemophilia and Thrombosis Center
    Code postal vérifié
    Aurora, États-Unis· Recrutement
  • University Of Miami Hospital
    Code postal vérifié
    Miami, États-Unis· Recrutement
  • St Joseph's Children's Hospital of Tampa
    Code postal vérifié
    Tampa, États-Unis· Recrutement
  • Innovative Hematology, Inc.
    Code postal vérifié
    Indianapolis, États-Unis· Recrutement
  • University Of Iowa Hospitals And Clinics
    Code postal vérifié
    Iowa City, États-Unis· Recrutement
  • University of Michigan - 1500 E Medical Center Dr
    Code postal vérifié
    Ann Arbor, États-Unis· Recrutement
  • M Health Fairview - Pediatric Specialty Clinic-Discovery
    Code postal vérifié
    Minneapolis, États-Unis· Recrutement
  • The University of Texas Health Science Center at San Antonio
    Code postal vérifié
    San Antonio, United States· Recrutement
  • Washington Center for Bleeding Disorders
    Code postal vérifié
    Seattle, United States· Recrutement
  • Arbesu Hematologia
    Code postal vérifié
    Godoy Cruz, Argentina· Recrutement
  • Instituto de Hematología Y Medicina Clínica Dr. Rubén Dávoli
    Code postal vérifié
    Rosario, Argentina· Recrutement

Questions fréquentes

What is haemophilia A?

Haemophilia A is a genetic condition where your blood doesn't clot properly due to a lack of a specific protein called Factor VIII, leading to longer bleeding after injuries.

What are 'inhibitors' in haemophilia?

Inhibitors are antibodies that your body can sometimes make against the treatment for haemophilia, which makes the standard medication less effective at stopping bleeds.

How will I know which treatment I'm getting?

You will be assigned to either NXT007 or emicizumab randomly, meaning you won't get to choose, and sometimes neither you nor your doctor will know which treatment you are on (this is called a 'blinded' study).

Quel type de tests vais-je avoir ?

You'll have regular physical exams, blood tests to check your clotting factors and general health, and you'll be asked about any bleeding episodes you experience.

Can I stop participating in the study?

Yes, you can leave the study at any time, for any reason. Your decision will not affect your future medical care.

Comment en savoir plus

Reference Study ID Number: BO45887 https://forpatients.roche.com/ No attachments to email below.

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Clinical Study to Evaluate the Effects of NXT007 Compared … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.